<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300075</url>
  </required_header>
  <id_info>
    <org_study_id>C-CUSABT-001</org_study_id>
    <nct_id>NCT04300075</nct_id>
  </id_info>
  <brief_title>The CUSA Clarity Bone Tip Study</brief_title>
  <official_title>Clinical Performance Investigation of the CUSA Clarity Bone Tip for Cranial Skull Base Bone Removal Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integra LifeSciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Study is to investigate the clinical performance and surgeon preferences of
      the CUSA Clarity Bone Tip during skull base surgery with removal of bony, and other cranial
      calcified tissue.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of bone removal to access lesion per surgeon assessment: Multifactorial 5-point Likert scale</measure>
    <time_frame>Surgery time</time_frame>
    <description>Multifactorial 5-point Likert scale (1 (worst) to 5 (best))</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cranial Skull Base Bone Removal</condition>
  <arm_group>
    <arm_group_label>CUSABT</arm_group_label>
    <description>Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CUSABT</intervention_name>
    <description>Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery</description>
    <arm_group_label>CUSABT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject requiring a cranial skull base procedure involving removal of bone with a
        ultrasonic aspirator
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 years of age

          -  Subject requires a cranial skull base procedure involving removal of bone with
             ultrasonic aspirator

          -  Subject is an appropriate candidate to receive use of the CUSA Clarity Bone Tip
             product during cranial skull base bone removal surgery, per the study surgeon

          -  Subject signed the IRB/EC-approved informed consent form demonstrating that the
             subject is willing and able to participate in this clinical study and to comply with
             all study procedures

        Exclusion Criteria:

          -  Subject is currently pregnant or plans to become pregnant prior to the study index
             surgery

          -  Subject has any significant medical condition that in the opinion of the investigator
             will interfere with protocol evaluation and participation

          -  Subject's surgical plan includes utilizing CUSA Clarity Bone Tip for bone removal
             anywhere besides the cranial skull base in an open craniotomy (e.g. transsphenoidal
             approach or spinal procedures).

          -  Subject is a prisoner or member of a different vulnerable population that should not
             be included in the study per the investigator or ethics committee.

        Intra-operative exclusion criteria :

          -  Surgeon does not utilize CUSA Clarity Bone Tip for cranial skull base bone removal
             during surgery or utilizes CUSA Clarity Bone Tip anywhere else besides the cranial
             skull base
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Marzuola</last_name>
    <role>Study Director</role>
    <affiliation>Integra LifeSciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marilyne Blanc</last_name>
    <phone>+33 437475937</phone>
    <email>marilyne.blanc@integralife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Tummon</last_name>
    <phone>+1 6099365490</phone>
    <email>andrew.tummon@integralife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Barbara Klinik</name>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Ewelt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Consorziale Policlinico</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Treviso</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Canova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

